Erzotabart

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A hexamerization-enhanced human immunoglobulin G1 (IgG1) monoclonal antibody that targets the cell surface glycoprotein CD-38 and carries the E430G mutation, with potential immunomodulating and antineoplastic activities. Upon administration, erzotabart targets and binds to CD38 on CD38-positive tumor cells, thereby forming antibody hexamers through increased intermolecular Fc-Fc interactions upon antigen binding. This may trigger direct cell killing, antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cell mediated phagocytosis (ADCP) and antibody-mediated complement dependent cytotoxicity (CDC) in CD38-expressing tumor cells. In addition, binding to CD38 by GEN3014 induces downmodulation of CD38, inhibits CD38 cyclase activity, and may abrogate immune suppression in the tumor microenvironment (TME). CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies.

**Synonyms:** - Anti-CD38 Monoclonal Antibody GEN3014 - ERZOTABART - GEN 3014 - GEN-3014 - GEN3014 - HexaBody-CD38